Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013‐2016

Megan G. Hofmeister, Elizabeth M. Rosenthal, Laurie K. Barker, Eli S. Rosenberg, Meredith A. Barranco, Eric W. Hall, Brian R. Edlin, Jonathan Mermin, John W. Ward, A. Blythe Ryerson – 6 November 2018 – Hepatitis C virus (HCV) infection is the most commonly reported bloodborne infection in the United States, causing substantial morbidity and mortality and costing billions of dollars annually.

A Regulatory Role of Apoptosis Antagonizing Transcription Factor in the Pathogenesis of Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma

Divya P. Kumar, Prasanna K. Santhekadur, Mulugeta Seneshaw, Faridoddin Mirshahi, Cora Uram‐Tuculescu, Arun J. Sanyal – 5 November 2018 – Hepatocellular carcinoma (HCC) is increasing as a cause of liver‐related mortality largely because of the growing burden of nonalcoholic steatohepatitis (NASH). The mechanisms of HCC development in nonalcoholic fatty liver disease (NAFLD) are incompletely understood. We initially identified apoptosis antagonizing transcription factor (AATF) to be associated with HCC in a mouse model of NASH that develops HCC without the addition of specific carcinogens.

Highly Diverse Hepatitis C Strains Detected in Sub‐Saharan Africa Have Unknown Susceptibility to Direct‐Acting Antiviral Treatments

Chris Davis, George S. Mgomella, Ana da Silva Filipe, Eric H. Frost, Genevieve Giroux, Joseph Hughes, Catherine Hogan, Pontiano Kaleebu, Gershim Asiki, John McLauchlan, Marc Niebel, Ponsiano Ocama, Cristina Pomila, Oliver G. Pybus, Jacques Pépin, Peter Simmonds, Joshua B. Singer, Vattipally B. Sreenu, Clara Wekesa, Elizabeth H. Young, Donald G. Murphy, Manj Sandhu, Emma C.

Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma

Michael J. Flynn, Anwar A. Sayed, Rohini Sharma, Abdul Siddique, David J. Pinato – 1 November 2018 – After a decade of stagnation in drug development, therapeutic reversal of immune‐exhaustion with immune checkpoint inhibitors (ICPIs) has been shown to be effective in advanced hepatocellular carcinoma (HCC). The clinical development of novel ICPIs continues at a rapid pace, with more than 50 clinical trials of immunotherapeutic agents registered as of May 2018 for this indication.

Subscribe to